Immunological features that associate with the strength of antibody responses to BNT162b2 mRNA vaccine against SARS-CoV-2.
BNT162b2
COVID-19
PBMC
SARS-CoV-2
Vaccine
naïve B cells
Journal
Vaccine
ISSN: 1873-2518
Titre abrégé: Vaccine
Pays: Netherlands
ID NLM: 8406899
Informations de publication
Date de publication:
25 03 2022
25 03 2022
Historique:
received:
15
07
2021
revised:
12
12
2021
accepted:
09
02
2022
pubmed:
5
3
2022
medline:
1
4
2022
entrez:
4
3
2022
Statut:
ppublish
Résumé
Predictive clinical factors associated with favorable responses to BNT162b2 mRNA vaccine against SARS-CoV-2 have been reported in some studies; however, there is a subgroup with low antibodytiters without well-known clinical factors reducing antibody responses. To clarify the immunological backgrounds that underlie the difference in antibody responses, we analyzed peripheral blood mononuclear cells (PBMCs) of each 20 individuals with a high anti-SARS-CoV-2 antibody titer and a low antibody titer out of 1774 healthcare workers who received BNT162b2 mRNA vaccine. A higher percentage of B cells before vaccination was associated with a higher antibody titer. Among B cells, naïve and transitional B cell frequencies were positively correlated with a higher antibody titer, whereas the frequencies of late memory B cells and plasmablasts were associated with a lower antibody titer. Fold change in the frequency of activated CD8
Identifiants
pubmed: 35241300
pii: S0264-410X(22)00192-X
doi: 10.1016/j.vaccine.2022.02.045
pmc: PMC8872843
pii:
doi:
Substances chimiques
Antibodies, Viral
0
COVID-19 Vaccines
0
Vaccines, Synthetic
0
mRNA Vaccines
0
BNT162 Vaccine
N38TVC63NU
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2129-2133Informations de copyright
Copyright © 2022 Elsevier Ltd. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Références
Cell. 2014 Apr 10;157(2):499-513
pubmed: 24725414
Cell. 2020 Aug 20;182(4):843-854.e12
pubmed: 32673567
J Mol Cell Biol. 2022 Jan 29;13(12):918-920
pubmed: 34450642
N Engl J Med. 2021 Apr 15;384(15):1412-1423
pubmed: 33626250
N Engl J Med. 2021 Feb 11;384(6):533-540
pubmed: 33369366
Nature. 2020 Oct;586(7827):127-132
pubmed: 32866963
Clin Microbiol Infect. 2021 Dec;27(12):1861.e1-1861.e5
pubmed: 34375755
Sci Immunol. 2021 Dec 10;6(66):eabl5842
pubmed: 34648356
Lancet. 2021 May 15;397(10287):1819-1829
pubmed: 33964222
Nature. 2021 May;593(7857):130-135
pubmed: 33684923
Sci Immunol. 2021 Jun 15;6(60):
pubmed: 34131023
Nat Immunol. 2016 Feb;17(2):204-13
pubmed: 26726811
Clin Infect Dis. 2021 Dec 6;73(11):2065-2072
pubmed: 33906236
Nat Commun. 2021 May 11;12(1):2670
pubmed: 33976165
Nature. 2021 Aug;596(7871):273-275
pubmed: 34111888
Am J Hematol. 2021 Jul 1;96(7):E257-E259
pubmed: 33837984